As a result, clinicians do not treat the starting doses as interchangeable, and a direct Mounjaro to Wegovy dose conversion is not considered medically appropriate
The STEP 1 trial, published in the New England Journal of Medicine, studied once-weekly semaglutide at 2.4mg in adults with overweight or obesity alongside lifestyle intervention
It functions as a dual GIP/GLP-1 receptor agonist, leveraging the bodys own mechanisms to control blood sugar and promote weight reduction
Patients often notice steadier energy levels, better exercise capacity, and gradual improvements in body composition
This test identifies your genetic predispositionssuch as GIPR rs1800437, GLP1R rs6923761, and MC4R rs17782313 variantsallowing your provider to select and dose your medication with greater precision
They can support digestive function and gut integrity (important if gastric emptying is slowed)